Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

LANDMARK DIAGNOSTICS, LLC

NPI: 1699172866 · HOUSTON, TX 77054 · Clinical Medical Laboratory · NPI assigned 12/03/2014

OIG Excluded Provider · This provider appears on the HHS Office of Inspector General List of Excluded Individuals/Entities. Exclusion date: 05/07/2024.
$119K
Total Medicaid Paid
5,531
Total Claims
4,214
Beneficiaries
25
Codes Billed
2018-01
First Month
2019-08
Last Month

Provider Details

Authorized OfficialSTEWART, TAYLOR (PRESIDENT)
NPI Enumeration Date12/03/2014

Related Entities

Other providers sharing the same authorized official: STEWART, TAYLOR

ProviderCityStateTotal Paid
MOMENT TO MOMENT LLP COLUMBUS OH $74K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 3,275 $44K
2019 2,256 $75K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 1,565 1,157 $29K
81162 35 33 $19K
81321 148 141 $14K
81298 145 139 $11K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1,154 766 $10K
81292 42 40 $7K
81295 147 141 $6K
81317 74 69 $4K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 228 211 $4K
81405 249 155 $3K
81404 230 138 $2K
81406 250 154 $2K
81323 39 36 $1K
81300 39 36 $1K
81297 26 24 $1K
81319 39 36 $976.80
81294 39 36 $971.52
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 233 179 $871.52
81403 163 155 $685.26
81242 139 133 $602.09
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 95 84 $94.40
81408 235 143 $0.00
81479 Unlisted molecular pathology procedure 49 48 $0.00
81201 142 136 $0.00
81203 26 24 $0.00